About TrovaGene, Inc.

Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. Its focuses on developing PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky and Hovsep Melkonyan on August 4, 1999 and is headquartered in San Diego, CA.

At the moment the company doesn't generate any revenue.

On its last earning announcement, the company reported a loss of -1.85$ per share.

The book value per share is 0.98$

TrovaGene, Inc. website


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
- -102.10% -16M - -15M -1.85 - - 9M 0.98 -13M - -13M